United Therapeutics Corporation
UTHR
$556.82
-$5.27-0.94%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 1.29B | 1.33B | 1.27B | 1.24B | 1.21B |
| Total Depreciation and Amortization | 88.40M | 85.60M | 82.50M | 79.70M | 77.30M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 359.60M | 247.40M | 104.60M | 101.60M | 81.70M |
| Change in Net Operating Assets | -172.10M | -106.50M | 97.40M | -52.10M | 42.10M |
| Cash from Operations | 1.56B | 1.56B | 1.56B | 1.37B | 1.41B |
| Capital Expenditure | -546.40M | -520.50M | -434.30M | -300.30M | -283.20M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 903.50M | -30.80M | -12.60M | -402.40M | -199.60M |
| Cash from Investing | 357.10M | -551.30M | -446.90M | -702.70M | -482.80M |
| Total Debt Issued | 200.00M | 200.00M | 200.00M | 200.00M | -- |
| Total Debt Repaid | -400.00M | -500.00M | -600.00M | -700.00M | -400.00M |
| Issuance of Common Stock | 235.50M | 183.10M | 109.70M | 101.50M | 135.50M |
| Repurchase of Common Stock | -2.56B | -1.02B | -1.02B | -21.20M | -16.10M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -11.50M | -11.50M | -11.50M | -11.50M | 0.00 |
| Cash from Financing | -2.54B | -1.15B | -1.32B | -431.20M | -280.60M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -620.20M | -140.10M | -213.80M | 237.40M | 648.40M |